Role of O-GlcNAc-ylation on tumor progression

O-GlcNAc 基化在肿瘤进展中的作用

基本信息

  • 批准号:
    10444126
  • 负责人:
  • 金额:
    $ 33.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-10 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

Abstract O-linked ß-N-acetylglucosamine (O-GlcNAc) is a sugar attachment to the side chain hydroxyl of a serine or threonine residue on proteins. O-GlcNAcylation controls key signaling and biological processes such as signal transduction, transcription, cell cycle progression, and metabolism. Perturbations in O-GlcNAc homeostasis have been linked with diabetes, cancer, and neurodegenerative diseases. Increased glucose levels channel flux through the Hexoseamine Biosynthetic Pathway (HBP), culminating in increased O-GlcNAc levels. The activity of HBP and consequently cellular O-GlcNAc-ylation are elevated in several cancer types, including breast cancer. We recently reported that inhibiting HBP activity significantly decreased the invasive phenotype of breast tumor cells. We surmised that abundance of glucose, a readily-metabolizable carbohydrate, will drive flux through HBP, resulting in enrichment of a portfolio of proteins that are modified by O-GlcNAc-ylation. Using unbiased proteomics analysis, we identified that elevated glucose culture conditions enrich for O-GlcNAc- modified GLI proteins, transcription factors of the Hedgehog (Hh) pathway. Importantly, we identified that in elevated glucose conditions, O-GlcNAc-modification of GLI exacerbates Hh/GLI activity; and inhibiting HBP mitigated this effect. We hypothesize that HBP-directed O-GlcNAc-ylation fundamentally programs invasive and chemoresistant attributes in tumor cells through activating Hh/GLI signaling. In Aim 1 we will determine the molecular underpinnings of HBP-directed O-GlcNAc-ylation of GLI. We will determine the causes and consequences of GLI O-GlcNAc-ylation. We will first identify engagement of the HBP in O-GlcNAc-modification of GLI proteins. Next, we will undertake investigations to identify establish the mechanistic basis of how HBP signaling engages O-GlcNAc-modified GLI to program invasive and chemoresistant attributes in tumor cells. In Aim 2 we will evaluate the impact of an elevated O-GlcNAc landscape on molecular and cellular attributes of the mammary tumor and the associated immune microclimate using two distinct and complementary syngeneic mouse models of mammary cancer. To enrich the relevance, we will also evaluate human TNBC and PDX model systems. We will test if inhibiting GLI activity, in the context of elevated O-GlcNAc, uncouples the influence of O- GlcNAc-ylation on invasive and chemoresistant attributes of mammary tumor cells. Relevance: Our proposed studies are structured to systematically investigate how O-GlcNAc-driven metabolic reprogramming in cancer cells connects at the molecular level to aberrantly activate Hh/GLI signaling. The cumulative outcomes will create mechanistic understanding of how O-GlcNAc-ylation programs tumor invasion, progression and response to anti-neoplastics.
摘要 O-连接的N-乙酰葡糖胺(O-GlcNAc)是连接到丝氨酸或半胱氨酸的侧链羟基的糖。 蛋白质上的苏氨酸残留。O-GlcNAc酰化控制关键的信号传导和生物过程,如信号传导 转导、转录、细胞周期进程和代谢。O-GlcNAc稳态的扰动 与糖尿病癌症和神经退行性疾病有关增加葡萄糖水平通道通量 通过己糖胺生物合成途径(HBP),最终导致O-GlcNAc水平升高。 HBP的活性和因此细胞O-GlcNAc-化在几种癌症类型中升高,包括 乳腺癌我们最近报道,抑制HBP活性可显著降低侵袭性表型, 乳腺肿瘤细胞的我们推测,丰富的葡萄糖,一种容易代谢的碳水化合物, 通过HBP的通量,导致通过O-GlcNAc-化修饰的蛋白质组合的富集。使用 无偏见的蛋白质组学分析,我们确定,高葡萄糖培养条件下富集O-GlcNAc- 修饰的GLI蛋白,刺猬(Hh)途径的转录因子。重要的是,我们发现, 在升高的葡萄糖条件下,GLI的O-GlcNAc修饰加剧Hh/GLI活性; 减轻了这种影响。我们假设HBP指导的O-GlcNAc-ylation从根本上调节了侵袭性和 通过激活Hh/GLI信号传导,在肿瘤细胞中具有化学抗性属性。 在目的1中,我们将确定GLI的HBP-指导的O-GlcNAc-化的分子基础。我们将 确定GLI O-GlcNAc-化的原因和后果。我们将首先确定HBP的参与情况 在GLI蛋白的O-GlcNAc修饰中。下一步,我们将进行调查,以确定 HBP信号传导如何使O-GlcNAc修饰的GLI参与编程侵入性和 肿瘤细胞的化学抗性属性。 在目标2中,我们将评估升高的O-GlcNAc景观对细胞的分子和细胞属性的影响。 乳腺肿瘤和相关的免疫微气候使用两种不同的和互补的同源基因, 小鼠乳腺癌模型。为了丰富相关性,我们还将评估人类TNBC和PDX模型 系统.我们将测试在O-GlcNAc升高的情况下,抑制GLI活性是否能解除O-GlcNAc的影响。 GlcNAc-化对乳腺肿瘤细胞的侵袭性和化疗耐药性的影响 相关性:我们提出的研究旨在系统地研究O-GlcNAc驱动的代谢 癌细胞中的重编程在分子水平上连接到异常激活Hh/GLI信号传导。的 累积的结果将产生对O-GlcNAc-ylation如何程序化肿瘤侵袭的机制理解, 进展和对抗肿瘤的反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lalita A. Shevde其他文献

Multi-faceted role of HSP40 in cancer
  • DOI:
    10.1007/s10585-009-9255-x
  • 发表时间:
    2009-04-02
  • 期刊:
  • 影响因子:
    3.200
  • 作者:
    Aparna Mitra;Lalita A. Shevde;Rajeev S. Samant
  • 通讯作者:
    Rajeev S. Samant
Emerging role of nuclear protein 1 (NUPR1) in cancer biology
  • DOI:
    10.1007/s10555-009-9183-x
  • 发表时间:
    2009-01-20
  • 期刊:
  • 影响因子:
    8.700
  • 作者:
    Uttio Roy Chowdhury;Rajeev S. Samant;Oystein Fodstad;Lalita A. Shevde
  • 通讯作者:
    Lalita A. Shevde
Informing the new developments and future of cancer immunotherapy
  • DOI:
    10.1007/s10555-021-09967-1
  • 发表时间:
    2021-05-18
  • 期刊:
  • 影响因子:
    8.700
  • 作者:
    Atul Kumar;Courtney A. Swain;Lalita A. Shevde
  • 通讯作者:
    Lalita A. Shevde
Erratum to: ‘Hedgehog signaling: modulation of cancer properties and tumor microenvironment’
  • DOI:
    10.1186/s12943-016-0522-6
  • 发表时间:
    2016-05-11
  • 期刊:
  • 影响因子:
    33.900
  • 作者:
    Ann Hanna;Lalita A. Shevde
  • 通讯作者:
    Lalita A. Shevde
The metastatic cascade through the lens of therapeutic inhibition
通过治疗性抑制视角看转移级联
  • DOI:
    10.1016/j.xcrm.2024.101872
  • 发表时间:
    2025-01-21
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Ian Miranda;Nusrat Jahan;Lalita A. Shevde
  • 通讯作者:
    Lalita A. Shevde

Lalita A. Shevde的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lalita A. Shevde', 18)}}的其他基金

Role of O-GlcNAc-ylation on tumor progression
O-GlcNAc 基化在肿瘤进展中的作用
  • 批准号:
    10589810
  • 财政年份:
    2022
  • 资助金额:
    $ 33.97万
  • 项目类别:
Roadmap for America's Cancer Explorers for the 21st Century (Race 21)
21 世纪美国癌症探索者路线图(第 21 场比赛)
  • 批准号:
    10252847
  • 财政年份:
    2020
  • 资助金额:
    $ 33.97万
  • 项目类别:
Roadmap for America's Cancer Explorers for the 21st Century (Race 21)
21 世纪美国癌症探索者路线图(第 21 场比赛)
  • 批准号:
    10478045
  • 财政年份:
    2020
  • 资助金额:
    $ 33.97万
  • 项目类别:
Roadmap for America's Cancer Explorers for the 21st Century (Race 21)
21 世纪美国癌症探索者路线图(第 21 场比赛)
  • 批准号:
    10023708
  • 财政年份:
    2020
  • 资助金额:
    $ 33.97万
  • 项目类别:
Mechanisms of resistance to cancer therapeutics
癌症治疗的耐药机制
  • 批准号:
    8694974
  • 财政年份:
    2014
  • 资助金额:
    $ 33.97万
  • 项目类别:
Mechanisms of resistance to cancer therapeutics
癌症治疗的耐药机制
  • 批准号:
    8830937
  • 财政年份:
    2014
  • 资助金额:
    $ 33.97万
  • 项目类别:
Mechanisms of resistance to cancer therapeutics
癌症治疗的耐药机制
  • 批准号:
    9079414
  • 财政年份:
    2014
  • 资助金额:
    $ 33.97万
  • 项目类别:
Molecular determinants of breast cancer malignancy
乳腺癌恶性肿瘤的分子决定因素
  • 批准号:
    8458999
  • 财政年份:
    2011
  • 资助金额:
    $ 33.97万
  • 项目类别:
Molecular determinants of breast cancer malignancy
乳腺癌恶性肿瘤的分子决定因素
  • 批准号:
    8653835
  • 财政年份:
    2011
  • 资助金额:
    $ 33.97万
  • 项目类别:
Molecular determinants of breast cancer malignancy
乳腺癌恶性肿瘤的分子决定因素
  • 批准号:
    8261842
  • 财政年份:
    2011
  • 资助金额:
    $ 33.97万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 33.97万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 33.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 33.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 33.97万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 33.97万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 33.97万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 33.97万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 33.97万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 33.97万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 33.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了